Related Experiment Videos
Quality control and stability of chemically and physically modified allergen extracts
W Geissler1, C Bünz, O Cromwell
1Allergopharma Joachim Ganzer KG, Reinbek bei Hamburg, Germany.
Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt Fur Sera Und Impfstoffe) Zu Frankfurt A.M
|January 1, 1994
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2008
Different allergenic activity of grass pollen allergens revealed by skin testing.
European journal of clinical investigation·2008
Clinical relevance of polymorphonuclear (PMN-) elastase determination in semen and serum during infertility investigation.
International journal of andrology·2008
Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
International archives of allergy and immunology·2007
Generation of a low immunoglobulin E-binding mutant of the timothy grass pollen major allergen Phl p 5a.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2007
A bright future for sublingual immunotherapy--contra.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Prospects for CpG based immunotherapy in asthma and allergy.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Understanding the immunological basis of asthma; immunotherapy and regulatory T cells.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Recombinant and modified allergens: the U.S. perspective.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Clinical trials with allergen products: in search of biological markers of efficacy.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Bridging Mechanisms and Strategies: MXene-Based Electrocatalysts for the Oxygen Evolution Reaction.
Nanomaterials (Basel, Switzerland)·2026
PLPPR3 and the making of neuronal filopodia.
Biological chemistry·2026
Hydroxylation Regulated Polar Interfaces for Enhanced Contact-Electro-Catalysis.
Advanced materials (Deerfield Beach, Fla.)·2026